David Lederman

New York, New York, United States
David Lederman is a Director in the Equity Capital Markets group at Chardan and has over 14 years of experience on Wall Street. He has been at Chardan since May of 2017 and primarily focuses on raising capital for healthcare and biopharma clients, both privately and publicly. Previously, David worked at Morgan Stanley from 2006-2017 in both the equity capital markets and investment banking groups.

David began covering the biopharma sector in 2016 and has helped public companies raise over $2Bn in initial public offerings and over $8Bn in follow-on offerings. Since joining Chardan, David has also executed notable private transactions for ReCode Therapeutics ($80MM Series A), Taysha GTx ($30MM Seed Financing) and Passage Bio ($116MM Series A). He has also been active in the biotech SPAC arena, recently leading IPOs for RTW’s second SPAC, HSAC 2 ($160MM), Life Sci’s first SPAC, LSAC ($66MM) and Chardan’s second biotech SPAC, CHAC 2 ($85MM).

He graduated Summa Cum Laude from Cornell University with a BS in Applied Economics and Management.
Speaking In
2:00 PM - 3:00 PM (PDT)
Wednesday, October 14
In July, the U.S. economy suffered from a 32.9% contraction in GDP, the largest in recent history…